Idorsia Pharmaceuticals Ltd.
idorsia.comTotal trials
99
Active
3
Phase 3
14
Total enrollment
17,876
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lucerastat | — | — | — | — | 7 | ||
| Daridorexant | — | — | 10 | ||||
| Non-orexin receptor antagonist medications for insomnia | — | — | — | — | — | 1 | |
| Non-orexin receptor antagonist insomnia medication | — | — | — | — | — | 1 |
Next readouts
- 2028-04
- 2029-08
- 2033-03
Top conditions
- Healthy Subjects30
- Healthy26
- Insomnia Disorder8
- Aneurysmal Subarachnoid Hemorrhage5
- Fabry Disease3
- Insomnia2
- Acute Heart Failure2
- Acute Decompensation of Chronic Heart Failure2
Frequently asked questions about Idorsia Pharmaceuticals Ltd.
- How many clinical trials does Idorsia Pharmaceuticals Ltd. have on ClinicalTrials.gov?
- Idorsia Pharmaceuticals Ltd. is listed as the lead sponsor on 99 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Idorsia Pharmaceuticals Ltd.'s trials are in Phase 3?
- 14 of Idorsia Pharmaceuticals Ltd.'s trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Idorsia Pharmaceuticals Ltd. focus on?
- Idorsia Pharmaceuticals Ltd.'s most-studied conditions on ClinicalTrials.gov are Healthy Subjects, Healthy, Insomnia Disorder, Aneurysmal Subarachnoid Hemorrhage, Fabry Disease.
- When are Idorsia Pharmaceuticals Ltd.'s next clinical trial readouts?
- Idorsia Pharmaceuticals Ltd. has 3 upcoming primary-completion readouts tracked here; the soonest is “Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)”, expected around 2028-04.